Palvella Therapeutics, Inc. (PVLA)
138.96
+7.62
(+5.80%)
USD |
NASDAQ |
Oct 09, 16:00
138.96
0.00 (0.00%)
After-Hours: 18:08
Palvella Therapeutics Price to Book Value : 9.224 for Oct. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 8.718 |
| October 07, 2026 | 8.669 |
| October 06, 2026 | 8.497 |
| October 05, 2026 | 8.773 |
| October 02, 2026 | 8.793 |
| October 01, 2026 | 8.811 |
| September 30, 2026 | 9.156 |
| September 29, 2026 | 9.227 |
| September 28, 2026 | 9.282 |
| September 25, 2026 | 9.171 |
| September 24, 2026 | 9.696 |
| September 23, 2026 | 9.928 |
| September 22, 2026 | 10.50 |
| September 21, 2026 | 10.18 |
| September 18, 2026 | 9.994 |
| September 17, 2026 | 10.24 |
| September 16, 2026 | 10.05 |
| September 15, 2026 | 10.04 |
| September 14, 2026 | 10.07 |
| September 11, 2026 | 9.966 |
| September 10, 2026 | 9.983 |
| September 09, 2026 | 10.05 |
| September 08, 2026 | 10.11 |
| September 04, 2026 | 10.44 |
| September 03, 2026 | 10.32 |
| Date | Value |
|---|---|
| September 02, 2026 | 10.15 |
| September 01, 2026 | 9.994 |
| August 31, 2026 | 10.13 |
| August 28, 2026 | 9.955 |
| August 27, 2026 | 9.979 |
| August 26, 2026 | 10.24 |
| August 25, 2026 | 9.840 |
| August 24, 2026 | 9.675 |
| August 21, 2026 | 9.429 |
| August 20, 2026 | 9.464 |
| August 19, 2026 | 9.954 |
| August 18, 2026 | 9.985 |
| August 17, 2026 | 10.19 |
| August 14, 2026 | 10.36 |
| August 13, 2026 | 10.39 |
| August 12, 2026 | 10.29 |
| August 11, 2026 | 10.24 |
| August 10, 2026 | 10.10 |
| August 07, 2026 | 10.47 |
| August 06, 2026 | 10.28 |
| August 05, 2026 | 10.28 |
| August 04, 2026 | 10.09 |
| August 03, 2026 | 9.345 |
| July 31, 2026 | 9.230 |
| July 30, 2026 | 9.970 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Agenus, Inc. | -- |
| Amgen, Inc. | 19.19 |
| BioCryst Pharmaceuticals, Inc. | -- |
| Imunon, Inc. | 1.203 |
| Curis, Inc. | 0.2768 |
Price to Book Value Related Metrics
| Price | 138.96 |
| Earnings Yield | -3.48% |
| Market Cap | 2.000B |